Journal of Clinical Oncology 临床肿瘤· Pieter Sonneveld·· 10 天前AI 评分25
Daratumumab 联合治疗新诊断多发性骨髓瘤长期无进展生存模型
Modeling Long-Term Progression-Free Survival in Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone
AI 导读
研究模型显示,Daratumumab 联合硼替佐米、来那度胺和地塞米松治疗新诊断多发性骨髓瘤患者的长期无进展生存期显著延长。
来源:Journal of Clinical Oncology 临床肿瘤 · ascopubs.org